Autopsy report · NCT03035630

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

“Principal investigator left lead institution and efforts to open the protocol at another institution were not successful.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Guru Sonpavde

Sponsor type

University, hospital or other

Conditions

Clear-cell Renal Cell Carcinoma; RCC; Kidney Cancer; Clear-cell Kidney Carcinoma

Interventions

Avelumab; Sunitinib

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Acute Lung Injury Ventilator Evaluation (ALIVE)
  “Lead Investigator no longer at Institution” (73% match in meaning)
• Laser Therapy in the Treatment of Post Thoracotomy Pain; A Pilot Study
  “Principal Investigator left the institution” (70% match in meaning)
• Lactobacillus Lozenges as Preventative Care in Low-grade Dysplasia
  “The study did not start as a key co-investigator left the institution.” (69% match in meaning)
• Digital Therapeutic Lifestyle Intervention Program for Patients With MASLD
  “Principal investigator left the institution and study was never funded” (69% match in meaning)
• Detailed Clinical, Biochemical and Genetic Characterization in Gonadotropin-releasing Hormone (GnRH) Deficiency Disorders
  “the Principal Investigator left the institution” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.